Abstract

IMPROVEMENT IN PURIFICATION METHODS OF MONTELUKAST INTERMEDIATE

Ohri Richa*, Aroshikha, Tomar Deepali and Sharma Sandeep

Abstract

Deplorably asthma is the most common chronic disease worldwide among children’s. Asthma is ranked 16th among the leading causes of years lived with disability and 28th among the leading cause of deaths with approximately 250,000 reported deaths annually. It affects around 23.5 million people (5-10%) including 7% of children. Montelukast is a potent antagonist of cysteinyl leukotrienes and it represents as the first category of drug which is effective in numerous biological and pathophysiological mechanisms involved in asthma. It improves theasthmatic symptoms, rescue pulmonary function and liberates medication use, and abridged the rate of exacerbation and the level of blood eosinophils, in mild-to-moderate asthmatics patients that were not treated with inhaled corticosteroids (ICS). The aim of present work is to improve the purification method of montelukast intermediate at 7th stage (MT07) of its manufacturing process. The quality improvement is achieved by using methanol in water as solvent in different ratios for purification to get better yield of more potent, stable and compatible drug in fewer expenses of time and money.

Keywords: Montelukast; Pathophysiology; Leukotrienes; Asthmatic; Potent and Compatible.